Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Spry vs T2D.com

Spry
Graded #409

Higher grade

vs+3.799999999999997
T2D.com
Graded #475

Lower grade

The verdict

Spry takes it — 56.8/100 to 53/100.

Spry grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Spry is a weight-loss and anti-aging telehealth platform pairing compounded semaglutide ($199/mo) and tirzepatide ($299/mo) with three longevity peptides — BPC-157, NAD+, and sermorelin ($249–$299/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSpry +25
54
29
Dose & formulationEven
64
64
Clinical oversightT2D.com +14
55
69
Labs & monitoringEven
52
52
FulfillmentSpry +3
61
58
Contract termsEven
55
55
Spry · left barT2D.com · right bar

The numbers

MetricSpryT2D.com
WeighScore56.8/10053/100
GradeCC
Scorecard rank#409#475
Semaglutide$199/mo (starting dose, compounded)$999/mo (starting dose, compounded)
Tirzepatide$299/mo (starting dose, compounded)$999/mo (starting dose, compounded)
CoverageCoverage not published1 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Spry

Graded #409 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
T2D.com

Graded #475 · C

Strengths

  • Built specifically for type 2 diabetic and pre-diabetic patients
  • Integrated service — prescriber, pharmacy, and delivery handled in one flow
  • Offers both compounded semaglutide and compounded tirzepatide
  • Temperature-controlled home delivery via UPS or FedEx
  • Ongoing prescriber monitoring and support included

Where it loses points

  • No pricing published on the public website — must register to see costs
  • No states list published on the site
  • Newer brand with limited independent reviews
  • Compounded only — no brand-name Ozempic, Wegovy, or Mounjaro

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard